Septerna, Inc. Retained Earnings
Septerna, Inc. (SEPN) had Retained Earnings of -$188.92 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-10
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$188.92M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$175.89M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$167.25M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$156.51M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$188.92M 10-Q · filed 2026-08-10 |
| 2026-03-31 | -$175.89M 10-Q · filed 2026-05-11 |
| 2025-12-31 | -$167.25M 10-Q · filed 2026-08-10 |
| 2025-09-30 | -$156.51M 10-Q · filed 2025-11-10 |
| 2025-06-30 | -$164.69M 10-Q · filed 2025-08-11 |
| 2025-03-31 | -$139.85M 10-Q · filed 2025-05-15 |
| 2024-12-31 | -$118.37M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$97.71M 10-Q · filed 2024-11-20 |
| 2023-12-31 | -$46.58M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |